

## Press Release

### **SYGNIS AG Strengthens Management Team with Appointment of Dr. Heikki Lanckriet**

**Appointment strengthens management team and is effective from 5 August 2016**

**Madrid, Spain and Heidelberg, Germany, 8 August 2016** – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced the appointment of Heikki Lanckriet, PhD, currently Chief Executive Officer (CEO) of Expedeon Holdings Ltd., as co-CEO and Chief Scientific Officer (CSO). The CSO role is a newly created position at SYGNIS. Dr. Lanckriet's appointment became effective on August 5, 2016. He will also become a member of the Management Board of SYGNIS, along with Pilar de la Huerta, who will serve as co-CEO and Chief Financial Officer (CFO) of the combined organization.

**Dr. Cristina Garmendia Mendizábal, Chairwoman of SYGNIS's Supervisory Board,** said: "We welcome Heikki to SYGNIS. With his track record in sales, marketing and operations and Pilar's experience in the international finance, these two executives have skill sets that are highly complementary. Their joint leadership will serve the company well as the combined organization advances towards achieving its ambitious goals."

Heikki Lanckriet, PhD, has co-founded Expedeon in 2003. At Expedeon, he has served as Chief Operating Officer, CSO and CEO, his current position, accumulating a deep knowledge of the life sciences tools and reagents business. Dr. Lanckriet holds a bachelor's and master's degree in biochemical engineering from the University of Ghent, Belgium and a PhD in biochemical engineering from the University of Cambridge, UK. He has published papers in peer-reviewed international scientific journals and is named inventor on a number of patents.

"I am very excited to have Heikki join me on the leadership team of SYGNIS," **Pilar de la Huerta, CEO and CFO of SYGNIS** commented. "Heikki's deep scientific background as well as his knowledge and experience on the operational side make him an ideal partner. I look forward to working together to lead the new company to future growth and success."

"I am pleased to have the opportunity to lead the combined organization with Pilar," said **Heikki Lanckriet, PhD.** "We have already worked together both before and during the acquisition and I am convinced that this will be a fruitful and productive collaboration. I look forward to working with the combined teams to achieve faster, sustained growth and create a thriving business."

**For further information please contact:**

**SYGNIS AG**

Pilar de la Huerta  
CEO/CFO  
Phone: +34 91 192 36 50  
Email: [pdelahuerta@sygnis.com](mailto:pdelahuerta@sygnis.com)

**MC Services AG**

Raimund Gabriel  
Managing Partner  
Phone: +49 89 210228 30  
Email: [raimund.gabriel@mc-services.eu](mailto:raimund.gabriel@mc-services.eu)

**About SYGNIS AG: [www.sygnis.com](http://www.sygnis.com)**

SYGNIS, headquartered in Germany and Spain, specializes in the development and commercialization of innovative products for DNA amplification and sequencing. Based on its proprietary technologies, SYGNIS has developed a commercial product portfolio addressing key challenges in the fast-growing fields of molecular biology and next-generation sequencing applications. Key products include the TruePrime™ product line and SensiPhi®, licensed to a leading industry partner, for whole genome DNA amplification and sequencing, as well as the SunScript™ Reverse Transcriptase product family to convert genetic information from RNA molecules back to DNA. SYGNIS AG is listed on the German Stock Exchange in the Prime Standard segment (Ticker: LIO1; ISIN: DE000A1RFM03).

**About Expedeon Holdings Ltd.: <http://www.expedeon.com/about>**

Expedeon Holdings Ltd. is privately held proteomics tools and reagents company headquartered in the UK. Expedeon is focused on providing high quality, simple and rapid solutions for protein research including RunBlue® gels for electrophoresis, the VersaWave spectrophotometer for quantitation or NVoy kits for refolding proteins to name just a few. Expedeon manufactures and sells a wide range of innovative, proprietary products through a direct sales force as well as well-established distribution channels. The company has manufacturing facilities in San Diego, California, USA and a representative office in Singapore.

### This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason.###